Compare AbCellera Biologics Inc (ABCL) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Quantumscape Corp — how do they compare? AbCellera Biologics Inc trades at $9.18 (market cap $2.85B), while Quantumscape Corp trades at $6.36 (market cap $3.81B). The key difference: Quantumscape Corp is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.
| ABCL | QS | |
|---|---|---|
Market Cap | $2.85B | $3.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $9.76 | $18.44 |
52-Week Low | $2.78 | $4.89 |
Enterprise Value | $2.45B | $3.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
QuantumScape (QS) trades at $6.075, up 9.86% in the last session, with a bullish technical signal overall despite mixed moving averages and oscillators. The company reported a net loss of $435.05 million in 2025, with negative ROE and ROA, and has no revenue as it develops solid-state battery technology. Recent news highlights partnerships with Volkswagen and Honda, but the stock fell 31% in July 2026 amid commercialization delays.
The outlook remains speculative, with potential upside tied to successful battery commercialization by 2029, but high execution risks and persistent losses warrant caution. Analyst sentiment is neutral to bearish, with 73% hold ratings, reflecting uncertainty over timelines and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
